MedKoo product information:

Trilostane

According to wikipedia.com, Trilostane is an inhibitor of 3 β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It is perhaps best known under the trade name Vetoryl. It was withdrawn from the United States market in April 1994. However, it was recently approved in 2008 for the treatment of Cushing's disease (hyperandrenocorticism) in dogs. It is also the first drug approved to treat both pituitary- and adrenal-dependent Cushing's in dogs. This prescription drug works by stopping the production of cortisol in the adrenal glands. In studies of the drug, the most common side effects were vomiting, lack of energy, diarrhea, and weight loss.  The safety and effectiveness of trilostane were shown in several studies. Success was measured by improvements in both blood test results and physical symptoms (increased appetite and activity level, and decreased panting, thirst and urination). Only one other drug, Anipryl (selegiline), is FDA-approved to treat Cushing's disease in dogs, but only to treat uncomplicated, pituitary-dependent Cushing's.

Current developer:   Stegram Pharmaceuticals Inc

 1: Koonce CJ, Walf AA, Frye CA. Trilostane exerts antidepressive effects among wild-type, but not estrogen receptor [beta] knockout mice. Neuroreport. 2009 Aug 5;20(12):1047-50. PubMed PMID: 19593916.

2: Igaz P, Tömböl Z, Szabó PM, Likó I, Rácz K. Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice. Curr Med Chem. 2008;15(26):2734-47. Review. PubMed PMID: 18991633.

3: Thomas JL, Bucholtz KM, Sun J, Mack VL, Kacsoh B. Structural basis for the selective inhibition of human 3beta-hydroxysteroid dehydrogenase 1 in human breast tumor MCF-7 cells. Mol Cell Endocrinol. 2009 Mar 25;301(1-2):174-82. Epub 2008 Oct 8. PubMed PMID: 18955108; PubMed Central PMCID: PMC2667100.

4: Benchekroun G, de Fornel-Thibaud P, Lafarge S, Gomez E, Begon D, Delisle F, Moraillon R, Héripret D, Maurey C, Rosenberg D. Trilostane therapy for hyperadrenocorticism in three dogs with adrenocortical metastasis. Vet Rec. 2008 Aug 9;163(6):190-2. PubMed PMID: 18689782.

5: Thomas JL, Mack VL, Glow JA, Moshkelani D, Terrell JR, Bucholtz KM. Structure/function of the inhibition of human 3beta-hydroxysteroid dehydrogenase type 1 and type 2 by trilostane. J Steroid Biochem Mol Biol. 2008 Jul;111(1-2):66-73. Epub 2008 May 3. PubMed PMID: 18524572; PubMed Central PMCID: PMC2580795.

6: Machida T, Uchida E, Matsuda K, Hirayama K, Yoshii K, Takiguchi M, Taniyama H. Aldosterone-, corticosterone- and cortisol-secreting adrenocortical carcinoma in a dog: case report. J Vet Med Sci. 2008 Mar;70(3):317-20. PubMed PMID: 18388437.

7: Nishikawa T, Saito J, Omura M. [Medical treatment for Cushing's syndrome]. Nippon Rinsho. 2008 Jan;66(1):186-91. Review. Japanese. PubMed PMID: 18186263.

8: Puddefoot JR, Barker S, Vinson GP. Trilostane in advanced breast cancer. Expert Opin Pharmacother. 2006 Dec;7(17):2413-9. Review. PubMed PMID: 17109615.

9: Barker S, Malouitre SD, Glover HR, Puddefoot JR, Vinson GP. Comparison of effects of 4-hydroxy tamoxifen and trilostane on oestrogen-regulated gene expression in MCF-7 cells: up-regulation of oestrogen receptor beta. J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):141-51. Epub 2006 Jun 27. PubMed PMID: 16806905.

10: Satoh F, Ito S. [Adrenocortical adenoma]. Nippon Rinsho. 2006 May 28;Suppl 1:710-3. Review. Japanese. PubMed PMID: 16776256.

11: Galac S, Kooistra HS, Voorhout G, van den Ingh TS, Mol JA, van den Berg G, Meij BP. Hyperadrenocorticism in a dog due to ectopic secretion of adrenocorticotropic hormone. Domest Anim Endocrinol. 2005 Apr;28(3):338-48. Epub 2005 Jan 11. PubMed PMID: 15760674.

12: Thomas JL, Umland TC, Scaccia LA, Boswell EL, Kacsoh B. The higher affinity of human type 1 3beta-hydroxysteroid dehydrogenase (3beta-HSD1) for substrate and inhibitor steroids relative to human 3beta-HSD2 is validated in MCF-7 tumor cells and related to subunit interactions. Endocr Res. 2004 Nov;30(4):935-41. PubMed PMID: 15666848.

13: Chang LL, Wun WS, Ho LL, Wang PS. Effects of dehydroepiandrosterone on corticosterone release in rat zona fasciculata-reticularis cells. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):487-95. Epub 2003 Nov 13. PubMed PMID: 14615881.

14: Skelly BJ, Petrus D, Nicholls PK. Use of trilostane for the treatment of pituitary-dependent hyperadrenocorticism in a cat. J Small Anim Pract. 2003 Jun;44(6):269-72. PubMed PMID: 12831104.

15: Eastwood JM, Elwood CM, Hurley KJ. Trilostane treatment of a dog with functional adrenocortical neoplasia. J Small Anim Pract. 2003 Mar;44(3):126-31. PubMed PMID: 12653328.

16: Puddefoot JR, Barker S, Glover HR, Malouitre SD, Vinson GP. Non-competitive steroid inhibition of oestrogen receptor functions. Int J Cancer. 2002 Sep 1;101(1):17-22. PubMed PMID: 12209583.

17: Füessl HS. [Secondary forms of hypertension. 5. Hypertension caused by Cushing syndrome and Conn's disease]. MMW Fortschr Med. 2002 Feb 28;144(9):42-4. German. PubMed PMID: 11921653.

18: Yamanaka K, Iitaka M, Inaba M, Morita T, Sasano H, Katayama S. A case of renin-producing adrenocortical cancer. Endocr J. 2000 Apr;47(2):119-25. PubMed PMID: 10943735.

19: Guarneri P, Cascio C, Piccoli T, Piccoli F, Guarneri R. Human neuroblastoma SH-SY5Y cell line: neurosteroid-producing cell line relying on cytoskeletal organization. J Neurosci Res. 2000 Jun 1;60(5):656-65. PubMed PMID: 10820437.

20: Williams CJ, Barley VL, Blackledge GR, Rowland CG, Tyrrell CJ, Bachelot F, Dermaille A, Fargeot P, Namer M, Pouillart J, et al. Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. Clin Oncol (R Coll Radiol). 1995;7(2):87-92. PubMed PMID: 7619769.

21: Ishido H, Yamashita N, Kitaoka M, Tanaka Y, Ogata E. A case of ectopic ACTH syndrome associated with Zollinger-Ellison syndrome: long-term survival with chemical adrenalectomy. Endocr J. 1994 Apr;41(2):171-6. PubMed PMID: 7951565.

22: Saito J, Nishikawa T. [Clinical usefulness of pharmacological treatment of Cushing's syndrome]. Nippon Rinsho. 1994 Mar;52(3):793-6. Review. Japanese. PubMed PMID: 8164384.

23: Murray R, Pitt P. Treatment of advanced breast cancer with formestane. Ann Oncol. 1994;5 Suppl 7:S11-3. PubMed PMID: 7873455.

24: Williams CJ, Barley VL, Blackledge GR, Rowland CG, Tyrrell CJ. Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. Br J Cancer. 1993 Dec;68(6):1210-5. PubMed PMID: 8260375; PubMed Central PMCID: PMC1968660.

25: Guarneri P, Papadopoulos V, Pan B, Costa E. Regulation of pregnenolone synthesis in C6-2B glioma cells by 4'-chlorodiazepam. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5118-22. PubMed PMID: 1317582; PubMed Central PMCID: PMC49240.

26: Rubens RD. Treatment of metastatic breast cancer and its complications. Curr Opin Oncol. 1991 Dec;3(6):1029-34. Review. PubMed PMID: 1668827.

27: Singh H, Jindal DP, Yadav MR, Kumar M. Heterosteroids and drug research. Prog Med Chem. 1991;28:233-300. Review. PubMed PMID: 1843548.

28: Takahashi M, Luu-The V, Labrie F. Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase activity. J Steroid Biochem Mol Biol. 1990 Oct;37(2):231-6. PubMed PMID: 2268554.

29: Nakada T, Koike H, Katayama T. Uneventful delivery following series of successive treatments for virilized Cushing syndrome due to adrenocortical carcinoma. Urology. 1990 Oct;36(4):359-63. PubMed PMID: 2219621.

30: Ingle JN, Krook JE, Schaid DJ, Everson LK, Mailliard JA, Long HJ, McCormack GW. Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and prior hormonal therapy exposure. Am J Clin Oncol. 1990 Apr;13(2):93-7. PubMed PMID: 2316487.

31: Nakada T, Furuta H, Katayama T, Sumiya H, Shimazaki J. The effect of adrenal surgery on plasma atrial natriuretic factor and sodium escape phenomenon in patients with primary aldosteronism. J Urol. 1989 Jul;142(1):13-8. PubMed PMID: 2525199.

32: Menashe Y, Shalev J, Serr DM. [RU-486: clinical application in gynecology]. Harefuah. 1989 May 10;116(10):532-5. Review. Hebrew. PubMed PMID: 2676767.

33: Chu PS, Buzdar AU, Hortobagyi GN. Trilostane with hydrocortisone in treatment of metastatic breast cancer. Breast Cancer Res Treat. 1989 Mar;13(2):117-21. PubMed PMID: 2659103.

34: Stimpel M, Ivens K, Volkmann HP, Wambach G, Kaufmann W. Therapeutic value of calcium antagonists in autonomous hyperaldosteronism. Klin Wochenschr. 1989 Feb 15;67(4):248-52. PubMed PMID: 2648061.

35: Iino Y, Izuo M, Takikawa H. Effects of trilostane on 7,12-dimethylbenz[a]anthracene-induced rat mammary cancers and body weight of rats in relation to estrogen receptors. Oncology. 1989;46(5):301-5. PubMed PMID: 2506498.

36: Williams CJ, Barley V, Blackledge G, Hutcheon A, Kaye S, Smith D, Keen C, Webster DJ, Rowland C, Tyrrell C. Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer. Cancer Treat Rep. 1987 Dec;71(12):1197-201. PubMed PMID: 3690530.

37: Tueni E, Devleeschouwer N, Leclercq G, Nijs M, Coune A, Vermeulen A, Paridaens R. Endocrine effects of Trilostane: in vitro and in vivo studies. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1461-7. PubMed PMID: 2824205.

38: Nakada T, Koike H, Katayama T. Evidence for a defect in urinary concentrating ability in primary aldosteronism and its reversal by adrenal surgery. Urol Int. 1987;42(4):295-301. PubMed PMID: 3672660.

39: Wilkinson JR, Williams JC, Singh D, Goss PE, Easton D, Coombes RC. Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response. Cancer Res. 1986 Sep;46(9):4862-5. PubMed PMID: 3731133.

40: Beardwell CG, Hindley AC, Wilkinson PM, St John J, Bu'lock D. Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone. Clin Endocrinol (Oxf). 1985 Oct;23(4):413-21. PubMed PMID: 4064349.

41: Adams EF, Ashby MJ, Burrin J, Yeo TH, Drucker R, Stringer K, Mashiter K. Effect of nivazol on ACTH secretion by human pituitary corticotrophic tumours in cell culture. Clin Endocrinol (Oxf). 1985 May;22(5):631-8. PubMed PMID: 2992847.

42: Coombes RC, Powles TJ, Muindi J, Hunt J, Ward M, Perez D, Neville AM. Trilostane therapy for advanced breast cancer. Cancer Treat Rep. 1985 Apr;69(4):351-4. PubMed PMID: 3995507.

43: Nakada T, Kazama T, Koike H, Yoshikawa M, Ishikawa S, Katayama T. Primary aldosteronism treated by trilostane (3 beta-hydroxysteroid dehydrogenase inhibitor). Urology. 1985 Feb;25(2):207-14. PubMed PMID: 2982227.

44: Winterberg B, Vetter W, Groth H, Greminger P, Vetter H. Primary aldosteronism: treatment with trilostane. Cardiology. 1985;72 Suppl 1:117-21. PubMed PMID: 3863713.

45: Nakada T, Kimura M. Primary aldosteronism associated with chronic renal failure. Report of a case. Int Urol Nephrol. 1984;16(2):165-73. PubMed PMID: 6469482.

46: Carlström K, Döberl A, Pousette A, Rannevik G, Wilking N. Inhibition of steroid sulfatase activity by danazol. Acta Obstet Gynecol Scand Suppl. 1984;123:107-11. PubMed PMID: 6238495.

47: Nakada T, Katayama T. [Therapeutic experience of primary aldosteronism associated with chronic renal failure]. Nippon Naibunpi Gakkai Zasshi. 1983 Sep 20;59(9):1219-27. Japanese. PubMed PMID: 6642011.

48: Dewis P, Anderson DC, Bu'lock DE, Earnshaw R, Kelly WF. Experience with trilostane in the treatment of Cushing's syndrome. Clin Endocrinol (Oxf). 1983 Jun;18(6):533-40. PubMed PMID: 6883729.

49: Beardwell CG, Hindley AC, Wilkinson PM, Todd ID, Ribeiro GG, Bu'Lock D. Trilostane in the treatment of advanced breast cancer. Cancer Chemother Pharmacol. 1983;10(3):158-60. PubMed PMID: 6861259.

50: Bricaire H, Luton JP. [Cushing's syndrome. Medical treatment of adrenal hypercorticism]. Horm Res. 1980;13(4-5):317-24. French. PubMed PMID: 7274999.

51: Komanicky P, Spark RF, Melby JC. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J Clin Endocrinol Metab. 1978 Nov;47(5):1042-51. PubMed PMID: 233687.